Full text is available at the source.
Intestinal dysbiosis leads to the reduction in neurochemical production in Parkinson’s disease (PD)
Gut bacteria imbalance linked to lower brain chemical levels in Parkinson's disease
AI simplified
Abstract
Intestinal dysbiosis is suggested to play a critical role in Parkinson's Disease progression.
- Parkinson's Disease is associated with motor and non-motor symptoms.
- Pathophysiological mechanisms of PD include alpha-synuclein aggregation, mitochondrial dysfunction, neuroinflammation, and oxidative stress.
- Dysbiosis may impact intestinal barrier function and contribute to neurotransmitter deficiencies, including dopamine, serotonin, and GABA.
- Current treatments involve levodopa and dopamine agonists, alongside gut health therapies like probiotics and Fecal Microbiota Transplantation.
- Future therapeutic directions may include synbiotics, engineered microbes, phage therapy, and the use of machine learning and artificial intelligence.
- Preventive strategies may involve lifestyle adjustments and early monitoring of gut health.
AI simplified